; and (cc) manufacturers shall calculate the actual ceiling price and shall offer to refund or credit the covered entity the difference between the estimated ceiling price and the actual ceiling price within 120 days of the determination by the manufacturer involved that an overcharge occurred. (viii) The prohibition against discriminatory distribution of drugs, consistent with the following: (I) A manufacturer shall make available each covered outpatient drug to covered entities on the same terms and conditions that the covered outpatient drug is offered to purchasers that are not covered entities except that the manufacturer will charge the covered entity for the covered outpatient drug at or below the ceiling price. (II) If the Secretary finds, after audit as described in subparagraph (B)(v) and after notice and hearing, that a manufacturer is in violation of the requirement described in subclause (I), the manufacturer shall be liable to the covered entity that was not able to purchase the covered outpatient drug involved at a discounted price in an amount equal to the reduction in the price of the drug provided under the agreement between the entity and the manufacturer under this section. . 6. Including programs funded under the Community Mental Health Services Block Grant or the Substance Abuse Prevention and Treatment Block Grant as covered entities (a) In general Section 340B(a)(4) of the Public Health Service Act ( 42 U.S.C. 256b(a)(4) ) is amended by adding at the end the following new subparagraph: (P) A program carried out through funds received under a grant under the Community Mental Health Services Block Grant or the Substance Abuse Prevention and Treatment Block Grant under part B of title XIX. . (b) Effective date The amendment made by subsection (a) shall apply beginning on the date of the enactment of this Act. 7. Preventing Medicare Hospital Outpatient Payment Cuts for Hospitals that Purchase Drugs under 340B Program (a) In general The Secretary of Health and Human Services shall not take any